A diagnosis of ductal carcinoma in situ (DCIS) might seem reassuring compared to invasive breast cancer, but recent research paints a more nuanced picture about this condition that affects roughly ...
A polygenic risk score (PRS) may help identify women who are at a greater risk of developing a future breast cancer after treatment for in situ breast disease, a retrospective study suggests. The ...
A study published in the International Journal of Radiation Oncology*Biology*Physics demonstrates that clinicopathology (CP) based risk assessment frequently fails to accurately assess recurrence risk ...
A retrospective study found that the 313-SNP breast cancer polygenic risk score (PRS 313) blood test could predict future incidents of breast cancer in women diagnosed with ductal carcinoma in situ ...
LAGUNA HILLS, Calif., March 12, 2026 /PRNewswire/ -- Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, announced today the publication of results from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results